US Brand Name(s)Gazyva
Use in Cancer Treatment:
Obinutuzumab is authorized for use in combination with other medicines to treat the following conditions: chronic lymphocytic leukemia (CLL). In individuals who have not yet been treated for CLL, it is used with chlorambucil.
Follicular lymphoma is a kind of lymphoma that affects the folli It is used to treat follicular lymphoma that has relapsed or has not responded to rituximab therapy. It is used in combination with bendamustine hydrochloride and then on its own to treat follicular lymphoma that has relapsed or has not responded to rituximab treatment.
In individuals with stage II bulky, stage III, or stage IV follicular lymphoma, chemotherapy is the first-line treatment. Patients who have achieved at least a partial remission are given obinutuzumab alone.
Obinutuzumab is also being researched for use in the treatment of various cancers.
An antineoplastic IgG1 monoclonal antibody that has been glycoengineered and humanized. Obinutuzumab, a type II anti-CD20 antibody of the third generation, binds to the extracellular domain of the human CD20 antigen on malignant human B cells with high selectivity. The antibody’s Fc region carbohydrates, which are rich in bisected non-fucosylated glycosylation variants, contribute to the antibody’s higher binding affinity for human FcgammaRIII receptors when compared to non-glycoengineered antibodies, resulting in increased antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. Furthermore, the significant apoptosis-inducing activity of R7159 following binding to CD20 on target cells might be explained by changes to elbow hinge sequences within the antibody variable framework regions.
Obinutuzumab Information on MedlinePlus – A summary of key information regarding this medication in layman’s terms, which may contain the following:
cautions about this medicine, what it’s used for and how it’s used, what you should tell your doctor before taking it, what you should know about it before using it, other drugs that might interact with it, and possible negative effects
Drugs are frequently investigated to see whether they can assist treat or prevent conditions other than those for which they have been authorised. Only authorised uses of the medication are covered by this patient information leaflet. Much of the material, though, might also apply to authorised uses that are being investigated.
